CagriSema
vs Semaglutide.
Compare CagriSema with semaglutide in REDEFINE 1 using randomized 68-week results, mechanisms, FDA status, dose context, and evidence limits.
What is the difference?
CagriSema and semaglutide were compared directly in the randomized Phase 3 REDEFINE 1 trial, which makes this comparison stronger than placing results from unrelated studies side by side. At 68 weeks, the trial-product estimand reported 22.7% mean weight loss with CagriSema and 16.1% with semaglutide. The same protocol used flexible dose escalation and compared CagriSema 2.4 mg/2.4 mg with semaglutide 2.4 mg in adults with obesity or overweight without type 2 diabetes. Those group results do not predict an individual winner. CagriSema remains investigational with an FDA application under review, while WEGOVY is an FDA-approved semaglutide product with product-specific labels and presentations.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
CagriSema
Submitted to FDA - not yet approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 30 matched NCT records
- Sponsor
- Novo Nordisk
Semaglutide
FDA-approved prescription drug
- Route
- Subcutaneous and oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Novo Nordisk Inc.
CagriSema vs Semaglutide: how direct is the evidence?
CagriSema and Semaglutide were randomized within REDEFINE 1. That provides direct group-level evidence for the exact population, doses, duration, endpoints, and analysis reported by the cited study. It does not create a universal winner outside that protocol.
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
One protocol, two randomized intervention groups.
Compare the randomized groups inside the cited protocol, then preserve its population, duration, dose, estimand, and reporting limits.
REDEFINE 1Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 5
- Results posted
- 0
- Recruiting site observations
- 155
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Compare the randomized groups inside the cited protocol, then preserve its population, duration, dose, estimand, and reporting limits.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
- Featured trial anchors
- NCT05567796 · NCT05669755 · NCT07011667
Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 215256
Compare the field, then read the limit.
REDEFINE 1 answers a question that most pipeline comparison pages cannot: how a fixed-dose cagrilintide plus semaglutide combination performed against semaglutide monotherapy under the same randomized protocol. The useful interpretation still depends on the estimand, flexible-dose design, adherence, discontinuation, population, background intervention, and exact semaglutide presentation. It does not turn CagriSema into approved supply or make every semaglutide product equivalent to the study arm.
| Field | CagriSema | Semaglutide | How to interpret it |
|---|---|---|---|
| Intervention | Cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination | Semaglutide 2.4 mg monotherapy | The combination adds an amylin analogue to GLP-1 receptor agonism, so the two randomized interventions are related but not interchangeable. |
| Direct study design | Randomized REDEFINE 1 CagriSema arm | Randomized REDEFINE 1 semaglutide arm | A common 68-week protocol provides direct evidence and avoids the largest errors created by comparing unrelated trials. |
| Trial-product result | 22.7% mean change at week 68 | 16.1% mean change at week 68 | These estimates describe the adherent-treatment question within REDEFINE 1 and are not guaranteed individual outcomes. |
| Treatment-policy result | 20.4% mean change at week 68 | 14.9% mean change at week 68 | Including outcomes regardless of adherence changes both estimates and better exposes why the statistical question must stay attached. |
| Regulatory status | Investigational; New Drug Application under FDA review | WEGOVY is FDA approved under NDA 215256 for defined uses | Direct trial evidence does not erase the status gap between an application under review and an approved product-specific label. |
Why the headline numbers do not name a winner.
Under the trial-product estimand, which estimates outcomes if participants adhered to randomized treatment, mean change at week 68 was 22.7% with CagriSema and 16.1% with semaglutide. Under the treatment-policy estimand, which includes results regardless of adherence, the reported means were 20.4% and 14.9%. REDEFINE 1 randomized 3,417 adults without type 2 diabetes and allowed flexible dosing. The study supports a direct group-level comparison inside that protocol, but it does not answer every dose, approved indication, diabetes population, product presentation, long-term outcome, safety preference, or individual response question.
Keep the comparison honest.
- 01
Keep the 22.7% and 16.1% trial-product estimates separate from the 20.4% and 14.9% treatment-policy estimates when quoting REDEFINE 1.
- 02
Describe the result as a direct 68-week randomized comparison in adults without type 2 diabetes, not as a universal forecast for every patient or indication.
- 03
Keep CagriSema's pending FDA application separate from WEGOVY approval, and never transfer either record to an online vial or unverified formulation.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →